Search

The article presents information about Rukobia Fostemsavir tromethamine, a HIV fusion inhibitor from ViiV Healthcare including uses, dosage and administration, mechanism of action, and contraindications.

The article offers brief information on the several U.S. Food & Drug Administration (FDA) approved drugs including Evotaz from Bristol- Myers Squibb Inc.; Avycaz from GlaxoSmithKline and Savaysa from Daiichi Sankyo Co. Ltd.

Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets. Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases. We analyse the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies. We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases. [ABSTRACT FROM AUTHOR]

Even before the partial success of a preventive HIV vaccine in a recent Phase III clinical trial, there had been an active research effort to determine one or more immune correlates of protection for HIV infection. This effort has been hampered by the lack of natural protective immunity against HIV. As a result, most of the studies have focused on long-term non-progressive infection or other clinical situations, none of which fully recapitulates protective immunity against HIV. Although this effort has been successful in defining characteristics of T cells in acute and non-progressive HIV infection, and has therefore greatly expanded our knowledge of the immunopathogenesis of AIDS, its success in defining immune correlates of protection is less clear. In this Opinion article we offer a perspective on how successful this effort has been in defining immune correlates of protection that have been, or will be, of use in the development of an HIV vaccine. Our view is that investing in an iterative approach to human vaccine efficacy trials of sufficient size and sampling frequency will improve the likelihood that an immune correlate of vaccine protection will be defined. [ABSTRACT FROM AUTHOR]

While the world is focused on controlling the spread of diseases such as HIV and malaria in the developing world, another approaching epidemic has been largely overlooked. The World Heath Organization predicts that there will be 16 million new cancer cases per year in 2020 and 70% of these will be in the developing world. Many of these cancers are preventable, or treatable when detected early enough. Establishing effective, affordable and workable cancer control plans in African countries is one step in the right direction toward limiting this epidemic. [ABSTRACT FROM AUTHOR]

Reviews the motion picture "Women's Voices Women's Lives," produced by Rosanna F. Demarco, Anne E. Norris and C. Abraham.

The article reviews the web site about human immunodeficiency virus (HIV) awareness and education located at "changethefaceofhiv.co.uk."

The article reviews the film "The Other City," directed by Susan Koch.

The article reviews web sites as resources for HIV/AIDS including http://aids.gov sponsored by the U.S. government, http://aidsinfo.nih.gov run by the U.S. Department of Health and Human Services, www.avert.org run by a British charity and www.who.int/hiv run by the World Health Organization (WHO).

The article describes some new drugs and dosage forms as of April 2016 which include Paricalcitol injection from Accord Healthcare, Palonosetron hydrochloride injection from Dr. Reddy's Laboratories, and Tetracaine hydrochloride ophthalmic solution from Alcon Laboratories.

The article evaluates the antiretroviral drug Odefsey for the treatment of HIV-1 infection from American biopharmaceutical company Gilead Sciences Inc.

This section presents an update on several drugs in the U.S., as of November 2006, including Gleevec, tamoxifen and the HIV drug Atripla.